GW Pharmaceuticals PLC- (GWPH) Scheduled to Post Earnings on Monday
GW Pharmaceuticals PLC- (NASDAQ:GWPH) is scheduled to post its quarterly earnings results before the market opens on Monday, December 4th. Analysts expect GW Pharmaceuticals PLC- to post earnings of ($1.72) per share for the quarter.
GW Pharmaceuticals PLC- (NASDAQ GWPH) opened at $122.95 on Friday. GW Pharmaceuticals PLC- has a twelve month low of $92.65 and a twelve month high of $136.95. The company has a quick ratio of 10.26, a current ratio of 10.39 and a debt-to-equity ratio of 0.02.
An institutional investor recently bought a new position in GW Pharmaceuticals PLC- stock. State Street Corp purchased a new stake in GW Pharmaceuticals PLC- (NASDAQ:GWPH) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,114 shares of the biopharmaceutical company’s stock, valued at approximately $212,000. 81.85% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts recently commented on the company. Maxim Group cut GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating and set a $61.00 target price for the company. in a report on Tuesday, August 8th. Cowen restated an “outperform” rating and set a $165.00 target price on shares of GW Pharmaceuticals PLC- in a report on Monday, October 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $208.00 price target on shares of GW Pharmaceuticals PLC- in a research report on Monday, October 2nd. Leerink Swann reaffirmed an “outperform” rating and issued a $160.00 price target (down previously from $162.00) on shares of GW Pharmaceuticals PLC- in a research report on Thursday, August 10th. Finally, BidaskClub lowered GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, four have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $144.55.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.